Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Parkinson's Research Now: Treatments Under Trial

From potential new treatments to failed trials, you may be wondering: what do these headlines mean for my life with Parkinson's? In this issue of Research Now, PDF's team reviews the treatments that may or may not be coming to a pharmacy near you.

In Development: Extended Release Drug May Be New Treatment Option

A new extended-release formulation of carbidopa-levodopa called IPX066 has been shown in a Phase III clinical trial to decrease "off-time" in people with Parkinson's disease, when compared with the standard immediate-release form of the drug. If and when this drug is available, it will provide another tool for people with PD and their doctors. Future research will be needed to compare its benefits to those of non-levodopa drugs with respect to off-time.

Learn More

International Update: Drug Available in Japan Shows Relief of Off-Time

A study conducted in Japan adds new evidence that istradefylline, a drug that has been investigated but not approved in the US, can reduce off-time in people with Parkinson's disease who are taking levodopa therapy. These latest results may help put istradefylline back on track to becoming a treatment option for people with PD in the US.

Learn More

Out of the Running: Drug Fails, Trial Helps Understanding of Gene Therapy

Ceregene, Inc., a company testing the potential of a gene therapy, CERE-120 (AAV-neurturin), has announced that its Phase 2b clinical trial failed to meet the end point that would have demonstrated the effectiveness of the treatment in easing the motor symptoms of Parkinson's disease.

Learn More

Lessons Learned

I urge you to browse our science news to read about these and other research results. One thing I will emphasize is that even "failed" clinical trials, such as the Ceregene one, can inform our understanding of Parkinson's and how to best treat it. If you have questions about these stories, please feel free to contact PDF's HelpLine, now available in nearly 200 languages, at (800) 457-6676 or info@pdf.org.

Browse More Science News


Connect with PDF on: Facebook / Blogger / Twitter / YouTube


Not getting these eblasts? Sign up to receive them in your inbox.

PDF's work in Parkinson's research, education and advocacy is made possible by your contributions. Make a donation today to support our mission. Thank you for your generosity.
 
If you have or believe you have Parkinson’s disease, then promptly consult a physician and follow your physician’s advice. This email is not a substitute for a physician’s diagnosis of Parkinson’s disease or for a physician’s prescription of drugs, treatment or operations for Parkinson’s.